A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial

Bernard Chevalier, Carlo Dimario, Franz-Josef Neumann, Donald E Cutlip, David O Williams, John Ormiston, Eberhard Grube, Robert Whitbourn, Jessie Coe, Lewis B Schwartz, ZOMAXX I Investigators, Kari Saunamäki

    6 Citations (Scopus)

    Abstract

    The ZOMAXX I trial tested the noninferiority of a zotarolimus-eluting coronary stent (ZoMaxx(™) ) when compared with a paclitaxel-eluting coronary stent (Taxus(™) Express(2™) ) in a randomized trial of percutaneous intervention for de novo coronary artery stenosis. Angiographic analysis at the primary endpoint of 9 months has been reported previously. The purpose of this follow-on analysis was to describe the clinical results of the ZoMaxx and Taxus cohorts of the ZOMAXX I trial after 5 years.
    Original languageEnglish
    JournalCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
    Volume82
    Issue number7
    Pages (from-to)1039-47
    Number of pages9
    ISSN1522-1946
    DOIs
    Publication statusPublished - 1 Dec 2013

    Fingerprint

    Dive into the research topics of 'A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial'. Together they form a unique fingerprint.

    Cite this